Please use this identifier to cite or link to this item:
http://repo.knmu.edu.ua/handle/123456789/23045
Title: | Kallistatin as a new non-invasive marker in patients with non-alcoholicfattyliver disease combined with hypertension |
Authors: | Rozhdestvenska, Anastasiia Zhelezniakova, Natalia |
Keywords: | NAFLD kallistatin hypertension |
Issue Date: | 2019 |
Citation: | Rozhdestvenska A. Kallistatin as a new non-invasive marker in patients with non-alcoholic fatty liver disease combined with hypertension / A. Rozhdestvenska, N. Zhelezniakova // Current and Emerging Diseases : Maltepe University International Student Congress, Maltepe University, Istanbul, Turkey, 16–17 May 2019. – Istanbul, 2019. – P. 58–59. |
Abstract: | Non-alcoholic fattyl liverdisease (NAFLD) affects between 15 and 50% of the adult population. Liver dysfunction and associated metabolic disturbances become a causeo f a high mortality rate. One of the main tasks of the diagnosis is to determine NAFLD at the initial stage called fatty steatohepatosis. Increased blood pressure accompanies NAFLD in 30% of cases and contributes to the rapid development of non-alcoholic steatohepatitis (NASH). Non-alcoholic fattyl liverdisease (NAFLD) affects between 15 and 50% of the adult population. Liver dysfunction and associated metabolic disturbances become a causeo f a high mortality rate. One of the main tasks of the diagnosis is to determine NAFLD at the initial stage called fatty steatohepatosis. Increased blood pressure accompanies NAFLD in 30% of cases and contributes to the rapid development of non-alcoholic steatohepatitis (NASH). Non-alcoholic fattyl liverdisease (NAFLD) affects between 15 and 50% of the adult population. Liver dysfunction and associated metabolic disturbances become a causeo f a high mortality rate. One of the main tasks of the diagnosis is to determine NAFLD at the initial stage called fatty steatohepatosis. Increased blood pressure accompanies NAFLD in 30% of cases and contributes to the rapid development of non-alcoholic steatohepatitis (NASH). Non-alcoholic fattyl liverdisease (NAFLD) affects between 15 and 50% of the adult population. Liver dysfunction and associated metabolic disturbances become a causeo f a high mortality rate. One of the main tasks of the diagnosis is to determine NAFLD at the initial stage called fatty steatohepatosis. Increased blood pressure accompanies NAFLD in 30% of cases and contributes to the rapid development of non-alcoholic steatohepatitis (NASH). |
URI: | https://repo.knmu.edu.ua/handle/123456789/23045 |
Appears in Collections: | Наукові роботи молодих вчених. Кафедра внутрішньої медицини № 1 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Rozhdestvenska A. (Kharkiv, Ukraine).docx | 15,78 kB | Microsoft Word XML | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.